MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ
0.6370
+0.0290
+4.77%
After Hours: 0.6052 -0.0318 -4.99% 17:24 03/10 EDT
OPEN
0.6100
PREV CLOSE
0.6080
HIGH
0.6546
LOW
0.5890
VOLUME
457.43K
TURNOVER
--
52 WEEK HIGH
11.41
52 WEEK LOW
0.5760
MARKET CAP
57.69M
P/E (TTM)
-0.3487
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VRCA last week (0303-0307)?
Weekly Report · 23h ago
Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 5d ago
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/03 13:15
Weekly Report: what happened at VRCA last week (0224-0228)?
Weekly Report · 03/03 12:01
Weekly Report: what happened at VRCA last week (0217-0221)?
Weekly Report · 02/24 12:00
VERRICA PHARMACEUTICALS INC - ENTERS WAIVER TO CREDIT AGREEMENT
Reuters · 02/21 21:22
VERRICA PHARMACEUTICALS - WAIVER INCLUDES REQUIREMENTS THAT THERE BE NO 'GOING CONCERN' QUALIFICATION FOR 2024 AND Q1 2025
Reuters · 02/21 21:22
Weekly Report: what happened at VRCA last week (0210-0214)?
Weekly Report · 02/17 11:57
More
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Webull offers Verrica Pharmaceuticals Inc stock information, including NASDAQ: VRCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRCA stock methods without spending real money on the virtual paper trading platform.